Skip to main content
padlock icon - secure page this page is secure

Oestradiol and FSH in gestational trophoblastic disease: a prospective analysis of their predictive value

Buy Article:

$47.00 + tax (Refund Policy)


To determine whether oestradiol or follicle-stimulating hormone (FSH) measured prior to treatment could improve the predictive value of the risk score used to determine treatment in cases of persistent gestational trophoblastic disease (GTD). Design 

Prospective observational study. Setting 

Tertiary referral centre for GTD. Population 

All women referred to Weston Park Hospital, Sheffield, with GTD between 1st January 1996 and 31st December 2000. Methods 

Blood was taken prior to the initiation of treatment to measure oestradiol and FSH. The results were analysed with respect to the time taken for the -hCG to return to normal. Main outcome measures 

Time taken to reach a normal -hCG. Results 

Data on 118 women were collected. Three women died of GTD during follow up. Using Cox's proportional hazards regression analysis, division of the risk scores into high and low risk groups (≤7, >7) demonstrated a significant difference with regard to the length of time taken to reach a normal -hCG level (hazard ratio 0.32; 95% CI: 0.18, 0.57) comparing high risk relative to low risk. However, addition of neither oestradiol nor FSH to the Cox regression analysis produced a significant hazard ratio (Ln oestradiol, 0.95; FSH 0.99). Division of the patients' risk scores into three groups of low (0–4), intermediate (5–7) and high (>7) risk groups produced similar results. Conclusions 

The measurement of neither oestradiol nor FSH appears to improve the prediction of outcome in persistent GTD when added to the risk score.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Department of Gynaecological Oncology, Liverpool Women's Hospital, Liverpool, UK 2: Trent Cancer Registry, Sheffield, UK 3: Sheffield Trophoblastic Disease Centre, Weston Park Hospital, Sheffield, UK 4: Department of Gynaecological Oncology, Royal Hallamshire Hospital, Sheffield, UK

Publication date: 01 July 2005

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more